NCT02173132

Brief Summary

This study evaluated the effects of acetyl-L-carnitine treatment on Perceived Work Stress, Work Ability and Work Performance in subjects with Hepatic Encephalopathy.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
94

participants targeted

Target at P25-P50 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2010

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2013

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

June 23, 2014

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 24, 2014

Completed
Last Updated

June 24, 2014

Status Verified

June 1, 2014

Enrollment Period

3.6 years

First QC Date

June 23, 2014

Last Update Submit

June 23, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • work stress

    90 days

Study Arms (2)

acetyl-L-carnitine

ACTIVE COMPARATOR

2 g acetyl-L carnitine twice a day for 90 days

Drug: Acetyl-L-carnitine

sugar pill

PLACEBO COMPARATOR

Placebo twice a day for 90 days

Other: Placebo

Interventions

acetyl-L-carnitine
PlaceboOTHER
sugar pill

Eligibility Criteria

Age33 Years - 68 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • overt hepatic encephalopathy (HE) or a history of overt HE

You may not qualify if:

  • history of recent alcohol intake; infection; recent antibiotic use or gastrointestinal bleeding; history of recent use of drugs affecting psychometric performances like benzodiazepines, antiepileptics or psychotropic drugs; a history of shunt surgery or transjugular intrahepatic portosystemic shunt for portal hypertension; electrolyte imbalance; renal impairment; hepatocellular carcinoma; severe medical problems such as congestive heart failure, pulmonary disease or neurological or psychiatric disorder that could influence quality of life measurement; inability to perform neuropsycological tests.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Catania

Catania, 95126, Italy

Location

MeSH Terms

Conditions

Occupational Stress

Interventions

Acetylcarnitine

Condition Hierarchy (Ancestors)

Occupational DiseasesStress, PsychologicalBehavioral SymptomsBehavior

Intervention Hierarchy (Ancestors)

CarnitineTrimethyl Ammonium CompoundsQuaternary Ammonium CompoundsAminesOrganic Chemicals

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

June 23, 2014

First Posted

June 24, 2014

Study Start

April 1, 2010

Primary Completion

November 1, 2013

Last Updated

June 24, 2014

Record last verified: 2014-06

Locations